KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Total Non-Current Liabilities (2016 - 2026)

Bio-Rad Laboratories has reported Total Non-Current Liabilities over the past 18 years, most recently at $2.7 billion for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 2.46% to $2.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.7 billion through Mar 2026, up 2.46% year-over-year, with the annual reading at $2.9 billion for FY2025, 11.7% up from the prior year.
  • Total Non-Current Liabilities was $2.7 billion for Q1 2026 at Bio-Rad Laboratories, down from $2.9 billion in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $4.0 billion in Q1 2022 and troughed at $2.6 billion in Q4 2024.
  • The 5-year median for Total Non-Current Liabilities is $3.3 billion (2023), against an average of $3.2 billion.
  • The largest YoY upside for Total Non-Current Liabilities was 29.58% in 2022 against a maximum downside of 22.85% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $3.7 billion in 2022, then dropped by 8.88% to $3.4 billion in 2023, then dropped by 22.16% to $2.6 billion in 2024, then rose by 11.7% to $2.9 billion in 2025, then dropped by 6.28% to $2.7 billion in 2026.
  • Per Business Quant, the three most recent readings for BIO's Total Non-Current Liabilities are $2.7 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.8 billion (Q3 2025).